Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.4.1209

Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans  

Kim, Mi-Yeong (Department of Internal Medicine, Seoul National University College of Medicine)
Kang, Sung-Yoon (Department of Internal Medicine, Seoul National University College of Medicine)
Lee, Suh-Young (Department of Internal Medicine, Seoul National University College of Medicine)
Yang, Min-Suk (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Min-Hye (Department of Internal Medicine, Seoul National University College of Medicine)
Song, Woo-Jung (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Sae-Hoon (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Yo-Jung (Department of Internal Medicine, Seoul National University College of Medicine)
Lee, Keun-Wook (Department of Internal Medicine, Seoul National University College of Medicine)
Cho, Sang-Heon (Department of Internal Medicine, Seoul National University College of Medicine)
Min, Kyung-Up (Department of Internal Medicine, Seoul National University College of Medicine)
Lee, Jong-Seok (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Jee-Hyun (Department of Internal Medicine, Seoul National University College of Medicine)
Chang, Yoon-Seok (Department of Internal Medicine, Seoul National University College of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.4, 2012 , pp. 1209-1215 More about this Journal
Abstract
Background and Aim: Oxaliplatin hypersensitivity is a well-known adverse reaction but the prevalence varies and data for frequency and clinical features have not been reported for Korea. Here we evaluates the prevalence and risk factors for hypersensitivity reactions to oxaliplatin after chemotherapy. Methods: Clinical information on all patients treated with oxaliplatin was retrospectively reviewed in electronic medical records between August 2009 and July 2010 in Seoul National University Bundang Hospital. Patients who experienced hypersensitivity reactions to oxaliplatin were compared with those who did not. Results: A total of 393 patients received oxaliplatin, with 42 (10.7%) experiencing hypersensitivity reactions including three cases of anaphylaxis. Median cycle of the first hypersensitivity reaction was 8. Reactions correlated with lower dexamethasone doses. Other variables were not significant. Conclusions: The prevalence of hypersensitivity reactions was 10.7%, symptoms being mostly mild and cutaneous. Lower dexamethasone doses could be a predictor for hypersensitivity reactions to oxaliplatin.
Keywords
Oxaliplatin; hypersensitivity; drug hypersensitivity; electronic health records;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51.   DOI   ScienceOn
2 Bajetta E, Pietrantonio F, Di Bartolomeo M, Buzzoni R (2010). Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori, 96, 154-6.
3 Basu R, Rajkumar A, Datta NR (2002). Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol, 7, 365-7.   DOI
4 Bautista MA, Stevens WT, Chen CS, et al (2010). Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol, 3, 12.   DOI
5 Bhargava P, Gammon D, McCormick MJ (2004). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 100, 211-2.   DOI
6 Brandi G, Pantaleo MA, Galli C, et al (2003). Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer, 89, 477-81.   DOI   ScienceOn
7 Collet E, Leguy-Seguin V, Jolimoy G, et al (2007). Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immun, 119, 726-30.   DOI
8 Faivre S, Chan C, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37.   DOI
9 Garufi C, Cristaudo A, Vanni B, et al (2003). Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 14, 497-8.   DOI
10 Gowda A, Goel R, Berdzik J, et al (2004). Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology, 18, 1671-5; discussion 6, 80, 83-4.
11 Ichikawa Y, Goto A, Hirokawa S, et al (2009). Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol, 39, 616-20.   DOI
12 Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7, 573-84.   DOI
13 Kidera Y, Satoh T, Ueda S, et al (2011). High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol, 16, 244-9.   DOI
14 Kim BH, Bradley T, Tai J, Budman DR (2009). Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology, 76, 231-8.   DOI
15 Koren C, Yerushalmi R, Katz A, et al (2002). Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol, 25, 625-6.   DOI
16 Lee KH, Park YJ, Kim ES, et al (2006). Hypersensitivity reactions to oxaliplatin. Cancer Res Treat, 38, 240-1.   DOI
17 Lee MY, Yang MH, Liu JH, et al (2007). Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer, 15, 89-93.   DOI
18 Lim KH, Huang MJ, Lin HC, et al. (2004). Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs, 15, 605-7.   DOI
19 Makrilia N, Syrigou E, Kaklamanos I, et al (2010). Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs, ??, ??.
20 Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005). Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer, 41, 2262-7.   DOI
21 Markman M, Kennedy A, Webster K, et al (1999). An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol, 125, 427-9.   DOI
22 Mason JM, Rees G (2010). Oxaliplatin-induced acute thrombocytopenia. J Oncol Pharm Pract, 17, 433-5.
23 Morgan JS, Adams M, Mason MD (1994). Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer, 30A, 1205-6.
24 Petit-Laurent F, Conroy T, Krakowski I, et al (2000). [Delayed urticaria with oxaliplatin]. Gastroenterol Clin Biol, 24, 851-2.
25 Polyzos A, Tsavaris N, Gogas H, et al (2009). Clinical features of hypersensitivity reactions to oxaliplatin: a 10- year experience. Oncology, 76, 36-41.   DOI
26 Polyzos A, Tsavaris N, Kosmas C, et al (2001). Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology, 61, 129-33.   DOI
27 Santini D, Tonini G, Salerno A, et al (2001). Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol, 12, 132-3.   DOI
28 Shao YY, Hu FC, Liang JT, et al. (2010). Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc, 109, 362-8.   DOI
29 Siu SW, Chan RT, Au GK (2006). Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol, 17, 259-61.   DOI
30 Shibata Y, Ariyama H, Baba E, et al (2009). Oxaliplatininduced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol, 14, 397-401.   DOI
31 Thomas RR, Quinn MG, Schuler B, Grem JL (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 97, 2301-7.   DOI
32 Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81.   DOI
33 Villee C, Tennstedt D, Marot L, et al (2010). Delayed urticaria with oxaliplatin. Contact Dermatitis, 63, 50-3.   DOI
34 Zanotti KM, Rybicki LA, Kennedy AW, et al (2001). Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol, 19, 3126-9.